Medicinal chemistry beyond KRAS: CDK2, WEE1, SERD
CID-078 is a cyclin A/B macrocycle; Circle Pharma reported early activity and acceptable safety at AACR.
Live at #AACR26: CID-078, a novel Cyclin A/B-RxL inhibitor, demonstrates promising early clinical activity with a favorable safety profile in advanced solid tumors, presented by Afshin Dowlati, MD (
@caseccc
).
Key takeaways:
• Novel oral macrocycle dual cyclin A/B RxL inhibitor.
Heat 8 · 6 likes · 0 replies · 2 reposts
Afshin Dowlati, Timothy A Yap, Antonio Giordano, Nehal J. Lakhani, William B McKean, Ildefonso Ismael Rodriguez Rivera, Vivek Subbiah, Kyaw Zin Thein, Judy S. Wang, Jinshu Fang, Li-Fen Liu, Peadar Cremin, Lukas Makris, Li-Pen Tsao, Lisa M. Kopp, Shivaani Kummar
Read the abstract →Source: Moffitt Cancer Center · x.com